Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Hepatology

• Publication date

  2007-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JHEP.2007.02.018PMID 17470380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

  2009cited by this paper
• 751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results

  2006cited by this paper
• The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002

  2006cited by this paper
• Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C

  2005cited by this paper
• Disposition and Metabolic Profiles of [14C]Viramidine and [14C]Ribavirin in Rat and Monkey Red Blood Cells and Liver

  2004cited by this paper
• Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection

  2004cited by this paper
• Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

  2004influential reference
• A Randomized Double-blind Placebo-controlled Trial

  2004cited by this paper
• Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design

  2003cited by this paper
• Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

  2003cited by this paper
• Activation and Deactivation of a Broad-Spectrum Antiviral Drug by a Single Enzyme: Adenosine Deaminase Catalyzes Two Consecutive Deamination Reactions

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

  2002cited by this paper
• Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C

  2002cited by this paper
• Gastric adenocarcinoma and kidney transplantation

  1998cited by this paper
• Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial

  1997cited by this paper
• Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.

  1996cited by this paper
• Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

  1995cited by this paper
• Ribavirin as Therapy for Chronic Hepatitis C

  1995cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect.

  2015cites this paper
• Hepatitis C virus associated glomerulopathies.

  2014cites this paper
• Chronic Hepatitis C among Immigrants Living in Canada: Natural History, Disease Burden, and Cost-effectiveness of Screening

  2013cites this paper
• новые перСпективы перСониФиЦированной терапии ХроничеСкого вируСного гепатита С

  2013cites this paper
• Anemia Management in Patients with Chronic Viral Hepatitis C

  2013cites this paper
• Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C

  2013cites this paper
• Hepatitis C virus: a new class of virus associated with particles derived from very low-density lipoproteins.

  2012cites this paper
• Drugs in Development for Hepatitis C

  2012cites this paper
• STRATEGIES FOR PREVENTION AND TREATMENT OF HEPATITIS C VIRUS INFECTION

  2012cites this paper
• A study of the natural history of hepatitis C infection within a geographically determined population (Trent HCV study)

  2012cites this paper
• Direct-acting antiviral therapy for chronic hepatitis C

  2012cites this paper
• The cryoglobulinaemias.

  2012cites this paper
• Taribavirin: potential future in the treatment of hepatitis C

  2011cites this paper
• Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico.

  2011cites this paper
• Taribavirin in the treatment of hepatitis C

  2011cites this paper
• Peginterferon and ribavirin treatment for hepatitis C virus infection.

  2011cites this paper
• New treatments for chronic hepatitis C virus infection.

  2011cites this paper
• Current Therapies for Chronic Hepatitis C

  2011cites this paper
• New trends in hepatitis C management.

  2010cites this paper
• Hepatitis C Treatment: current and future perspectives

  2010cites this paper
• An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 1. Validity of the Chimpanzee Model

  2010cites this paper
• An Assessment of the Use of Chimpanzees in Hepatitis C Research Past , Present and Future : 1 . Validity of the Chimpanzee Model

  2010cites this paper
• Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.

  2010cites this paper
• Management of hepatitis C virus-related mixed cryoglobulinemia.

  2010cites this paper
• The next step for taribavirin

  2010cites this paper
• Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV – the role of epoetin, G‐CSF and novel agents

  2010cites this paper
• Ribavirin and Viramidine

  2010cites this paper
• Ribavirin monotherapy for chronic hepatitis C.

  2009cites this paper
• Ribavirin analogs.

  2009cites this paper
• The changing face of HIV/AIDS in treated patients.

  2009cites this paper
• New therapies for hepatitis C virus infection.

  2009cites this paper
• Hepatitis C virus infection and immunomodulatory therapies.

  2009cites this paper
• Hepatitis C virus virology and new treatment targets

  2009cites this paper
• [Hepatitis C: the recovery].

  2009cites this paper
• Taribavirin: a potential alternative to ribavirin

  2009cites this paper
• Development of novel treatments for hepatitis C.

  2009cites this paper
• Emerging antiviral drugs for hepatitis C virus.

  2009cites this paper
• What future for ribavirin?

  2009cites this paper
• Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents

  2009cites this paper
• Prognosis of hepatitis C virus‐infected Canadian post‐transfusion compensation claimant cohort

  2009cites this paper
• A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment‐naïve patients with chronic hepatitis C: ViSER1 results

  2009cites this paper
• The Utility of Therapeutic Drug Monitoring for Ribavirin in Patients with Chronic Hepatitis C—A Critical Review

  2009cites this paper
• New developments in the antiviral treatment of hepatitis C

  2009cites this paper
• HépatologieHépatite C : la guérisonHepatitis C: The recovery

  2009cites this paper
• Sequential antiviral and iron chelation treatment in a teenage boy with congenital anemia, chronic hepatitis C, and secondary hemosiderosis.

  2009cites this paper
• Novel therapies in hepatitis B and C

  2008cites this paper
• Taribavirin for the treatment of chronic hepatitis C

  2008influential citation
• Emerging drugs for hepatitis C

  2008cites this paper
• The Present And Emerging Investigational Drugs For Chronic Hepatitis C: Current Status

  2008cites this paper
• Novel hepatitis C drugs in current trials.

  2008cites this paper
• complicationsviral hepatitis C: efficacy, side effects, and

  2007cites this paper
• The “C” of Viral Hepatitis in Children

  2007cites this paper
• Anemia and clinical outcomes in hepatitis C.

  2007cites this paper
• Development of a therapeutic vaccine against the hepatitis C virus

  2007cites this paper
• The "C" of viral hepatitis in children.

  2007cites this paper
• Treatment of hepatitis C virus infection.

  2007cites this paper
• New treatment strategies against hepatitis C viral infection.

  2006cites this paper
• Treating viral hepatitis C: efficacy, side effects, and complications

  2006cites this paper